Immunogenicity of pandemic influenza A (H1N1)vaccine
Showing 1 - 25 of >10,000
Influenza, Human Trial in Estonia, Philippines (H5N1 antigen combined with MF59 adjuvant)
Completed
- Influenza, Human
- H5N1 antigen combined with MF59 adjuvant
-
Tallinn, Harjumaa, Estonia
- +6 more
Jul 21, 2022
Influenza, Pandemic Trial in Baltimore (BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette -
Recruiting
- Influenza, Pandemic
- BW-1014: 25 µg rH5 in 20% NE - pipette - IN
- +5 more
-
Baltimore, MarylandCenter for Vaccine Development and Global Health, University of
Jul 8, 2022
Influenza A, Pandemic Influenza Trial in Oslo (H7HLAII)
Recruiting
- Influenza A
- Pandemic Influenza
- H7HLAII
-
Oslo, NorwayOslo University Hospital
Sep 20, 2023
Pandemic Influenza Trial in United States (A/H5N1, LT Adjuvant Patch)
Completed
- Pandemic Influenza
- A/H5N1
- LT Adjuvant Patch
-
Anaheim, California
- +5 more
Dec 9, 2021
Influenza Trial in South Jordan (mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only)
Recruiting
- Influenza
- mRNA-1018 for H5N8
- +4 more
-
South Jordan, UtahJ. Lewis Research, Inc/Jordan River Family Medicine
Jul 25, 2023
Pandemic Influenza Disease Trial in Tampere, München (Placebo (PL), Trivalent influenza virus vaccine (TIV), Adjuvanted
Completed
- Pandemic Influenza Disease
- Placebo (PL)
- +3 more
-
Tampere, Finland
- +1 more
Apr 22, 2021
Influenza Trial in Baltimore (H5N1 pISV)
Completed
- Influenza
- H5N1 pISV
-
Baltimore, MarylandCenter for Immunization Research, Johns Hopkins Bloomberg School
Feb 15, 2022
Influenza, Human Trial (FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A)
Not yet recruiting
- Influenza, Human
- FLU Q-PAN H5N8 Formulation 1
- +3 more
- (no location specified)
Jul 27, 2023
Influenza Trial in Iowa City (DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride,
Not yet recruiting
- Influenza
- DCVC H1 HA mRNA vaccine
- +2 more
-
Iowa City, IowaUniversity of Iowa Hospitals & Clinics - Department of Internal
Jul 6, 2023
Influenza, Human, Infections, Respiratory Tract Infections Trial in United States (aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on
Not yet recruiting
- Influenza, Human
- +4 more
- aH5N8c on Day 1
- +4 more
-
Cullman, Alabama
- +8 more
May 15, 2023
Influenza Trial in Toronto, Mirabel, Pointe-Claire (H1 influenza antigen)
Completed
- Influenza
- H1 influenza antigen
-
Toronto, Ontario, Canada
- +2 more
Nov 3, 2023
Influenza Vaccine Trial in United States (Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo)
Completed
- Influenza Vaccine
- Cam2020 M2SR H3N2 influenza vaccine
- +3 more
-
Port Orange, Florida
- +5 more
Nov 11, 2022
Influenza, Human Trial (sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3)
Not yet recruiting
- Influenza, Human
- sa-mRNA vaccine Dose 1
- +4 more
- (no location specified)
Sep 7, 2023
Influenza, Human Trial in Brisbane (ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine
Not yet recruiting
- Influenza, Human
- ARCT-2138
- +2 more
-
Brisbane, Queensland, AustraliaNucleus Network Brisbane Clinic
Nov 8, 2023
Influenza Trial in Durham (Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP
Not yet recruiting
- Influenza
- Influenza Virus Quadrivalent Inactivated Vaccine
- +2 more
-
Durham, North CarolinaDuke Human Vaccine Institute - Duke Vaccine and Trials Unit
Feb 23, 2023
Influenza, Human, Infections, Respiratory Tract Infections Trial in Philippines, United States (Low dose A/H2N3c + standard dose
Not yet recruiting
- Influenza, Human
- +4 more
- Low dose A/H2N3c + standard dose MF59
- +5 more
-
Rockville, Maryland
- +7 more
May 26, 2023
Influenza, Human, Influenza in Birds, Respiratory Tract Infections Trial in United States (aH5N6c on Day 1, aH5N6c on Day 22,
Recruiting
- Influenza, Human
- +7 more
- aH5N6c on Day 1
- +2 more
-
Huntsville, Alabama
- +17 more
Jul 26, 2022
Influenza, Human Trial in Morayfield (CODA-VAX H1N1, Flucelvax Quad, Saline)
Active, not recruiting
- Influenza, Human
- CODA-VAX H1N1
- +2 more
-
Morayfield, Queensland, AustraliaAmy Goh, Study Coordinator
Jun 24, 2022
Influenza Vaccine Trial in Anaheim, DeLand, Lenexa (Sing2016 M2SR H3N2 influenza vaccine, Placebo)
Active, not recruiting
- Influenza Vaccine
- Sing2016 M2SR H3N2 influenza vaccine
- Placebo
-
Anaheim, California
- +2 more
May 13, 2022
H1N1v Influenza Trial in Gentofte/Copenhagen, Næstved (Focetria)
Completed
- H1N1v Influenza
- Focetria
-
Gentofte, Denmark
- +1 more
Nov 14, 2022
Influenza Trial in Raymond Terrace (OVX836 480µg, Quadrivalent Inactivated Influenza Vaccine (Brand 1), Quadrivalent Inactivated
Not yet recruiting
- Influenza
- OVX836 480µg
- +3 more
-
Raymond Terrace, Brisbane, AustraliaMater Misericordiae University Hospital
Feb 9, 2023
Influenza, Influenza, Human, Influenza Viral Infections Trial in Russian Federation (Influenza vaccine [inactivated])
Recruiting
- Influenza
- +3 more
- Influenza vaccine [inactivated]
-
Ekaterinburg, Russian Federation
- +6 more
Feb 13, 2023
Influenza, Human Trial (Investigational aQIVc, licensed QIV1, licensed QIV2)
Not yet recruiting
- Influenza, Human
- Investigational aQIVc
- +2 more
- (no location specified)
Aug 28, 2023
Influenza Prevention Trial in Lenexa, Metairie, Cincinnati (INFLUENZA G1 mHA, Placebo, Al(OH)3)
Recruiting
- Influenza Prevention
- INFLUENZA G1 mHA
- +2 more
-
Lenexa, Kansas
- +2 more
Jun 5, 2023
Avian Influenza, H1N1 Influenza, Influenza Trial in Nashville (AS03, Influenza Virus Vaccine, Monovalent A/H3N2v
Completed
- Avian Influenza
- +2 more
- AS03
- +2 more
-
Nashville, TennesseeVanderbilt University Medical Center - Vanderbilt Institute for
Jan 25, 2022